GSK’s dostarlimab shows promise in endometrial cancer
The trial’s primary endpoints were confirmed objective response rate and duration of response
Read More
Tag: dostarlimab
GSK’s endometrial cancer drug to be filed later this year
GlaxoSmithKline group Tesaro has presented mid-stage data indicating “robust activity” of its anti-PD-1 therapy dostarlimab in patients with advanced or recurrent endometrial cancer, with a filing now on the cards for later this year.
Read More
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
- Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
- Exdensur approved in EU for severe asthma and CRSwNP
- Axol Bioscience acquires Newcells Biotech ophthalmology unit
- Nuclera and leadXpro partner to accelerate structure‑based drug design
